@CoMind_ is hiring! At CoMind we are working to redefine the way the brain is measured and treated to optimise patient outcomes across the care continuum. Our first product is a non-invasive neuromonitoring device, which will be used on patients in the ICU and surgery. In the

What startups are building AI tools for analog design, PCB layout, EMC/SI analysis, etc? If no one’s doing this well, happy to seed a couple of people to build a demo and then trial it at CoMind and Flux.

Rob will also be participating in a Panel Discussion: Neurophotonics Industry and Relationships With Academia - 3:00 PM Sunday 26 Jan (PST) | Moscone South, Room 105 (Level 1 Lobby) We look forward to sharing our work and engaging in valuable discussions!

Monte Carlo simulations of time-of-flight resolved blood flow index: times-of-flight beyond 1 ns permit selective measurement of pulsatile cerebral blood flow Dominic Hill, Research Data Scientist 3:00 PM (PST) Tuesday 28 Jan | Moscone South, Room 213 (Level 2)

Measuring cerebral blood flow at late times-of-flight with CoMind R1: A multichannel interferometric optical neuromonitoring system Tanja Dragojevic, Translational Optics Lead 9:40 AM (PST) Sunday 26 Jan | Moscone South, Room 105 (Level 1 Lobby)

CoMind R1: a multichannel interferometric optical system for real-time blood flow measurements at late times-of-flight Veronika Parfentyeva, Senior Optical Research Scientist 4:30 PM (PST) Saturday 25 Jan | Moscone South, Room 105 (Level 1 Lobby)

Developing a product-ready optical sensing platform for non-invasive measurement of cerebral blood flow dynamics (Invited Paper) Rob Cooper, Chief Scientific Officer 2:20 PM (PST) Sunday 26 Jan | Moscone South, Room 105 (Level 1 Lobby)

CoMind is excited to announce that after several years of advancing our unique optical neuromonitoring technology, we will be presenting our work for the first time at SPIE Photonics West in San Francisco this weekend (25th-30th). Please see below our talks and speakers:

We are thrilled to announce the appointment of Michael Tarnoff, MD to CoMind's Board of Directors. Mike is an incredibly experienced operator, previously served as CEO at @TuftsMedicalCtr in Boston, from 2020 to 2024, and has been a surgeon at Tufts since 2001, becoming

We're just 4 weeks away from #LSIEurope24, but the buzz is already building amongst leading #investors, #strategics, and #innovators for #LSIUSA25 in #DanaPoint, #California. After reviewing applications from global leaders working to build breakthrough #Medtech and #Healthtech

CoMind welcomes Marc to the team and is excited to start this journey with him.

he has advised some of the world's most successful medical device companies in the development of new products, and lectured all over the world. Marc brings a wealth of knowledge to the table in the development of the next generation of neurotechnologies with CoMind.

He previously served as the Director of Perioperative Technology and co-director of the Neuroanesthesia division at NYU Langone Medical Centre. With his expertise in the fields of anesthesiology and biomedical engineering,

He has served as the past president of the American Society of Neurophysiologic Monitoring and boasts more than four decades of experience with the American Society of Anesthesiology and the Society for Neuroscience in Anesthesiology and Critical Care.

CoMind is thrilled to announce the addition of a new leader to the team: Marc Bloom as our Chief Medical Officer. Marc comes to us with an impressive background as the previous Chief of Neuroanaesthesiology and Professor at the University of Miami.

strategic direction of CoMind and our continued growth. CoMind welcomes Allie to the team and is excited to start this journey with her.

This makes her the perfect fit to lead CoMind's product strategy and product development roadmap. Allie will be responsible for defining CoMind's first product and building our future product portfolio to ensure market success, and will play an instrumental role in the

She started as an R&D Engineer and rose to lead global product management for Tissue Oximetry and Pressure Monitoring at Edwards Lifesciences. Allie's background in physics, coupled with an MBA from NYU Stern.

🟢 Our collaborative research with @babylonhealth and @CoMind_ introduced a novel statistical measure called counterfactual harm. The work demonstrates how to overcome problems with standard approaches to avoid pursuing harmful policies:

Optics people- come and work with us at CoMind! Great people, great tech, great vision. #fNIRS #neuroimaging Senior Optical Engineer - Experimental Optics